title: Placental Molar Disease: What are the Benefits and Barriers to the Adoption of a Comprehensive Diagnostic Service?
abstract: The molecular cytogenetic analysis of specimens (genotyping) suspicious for hydatidiform mole (HM) significantly improves diagnostic accuracy over histopathology and immunohistochemical analysis alone, particularly in the classification of partial mole. However, the implementation of this advance in diagnostics has been slow. This study sought to identify the major benefit and potential barriers to the adoption of genotyping. A pilot Placental Molar Diagnostic (PMD) Service was established combining histopathology, p57 immunohistochemistry, and molecular genotyping analysis for both in-house and referred-in cases suspicious for HM or with a preliminary diagnosis of HM. A retrospective analysis of 117 cases received in the first 16 mo was conducted to identify the utility of the PMD Service and factors or barriers which precluded optimal results. A final diagnosis of HM was made in 73 cases (37 complete HMs and 36 partial HMs). The remaining 44 cases were hydropic abortuses. Three potential barriers were identified that could lead to less than optimal results from a PMD Service: prevalence of noninformative genotyping, lack of any available or appropriate paraffin blocks, and inappropriate deferral of genotyping. The major utility of this pilot PMD Service was to increase the specificity of a diagnosis of HM, and avoid unnecessary clinical follow-up in 37% of cases with an initial suspicion or diagnosis of HM. Measures can be undertaken to address potential barriers to the implementation of a comprehensive placental diagnostic platform. Underutilization of molecular genotyping in the diagnosis of HM likely leads to inappropriate management and "downstream" costs in a significant proportion of patients suspected of having HM.
authors: Division of Diagnostic Medical Genetics (E.K.), Mount Sinai Hospital Division of Diagnostic Medical Genetics (G.M.), Mount Sinai Hospital Section of Gynecological Pathology (S.N., M.C.C.) and Division of Diagnostic Medical Genetics (M.V.), Mount Sinai Hospital Division of Gynecologic Oncology (J.D.), Mount Sinai Hospital and University Health Network Section of Gynecological Pathology (T.J.C.), Mount Sinai Hospital, Toronto, ON, Canada.
authors: Elena
authors: E
authors: Kolomietz
authors: Georges
authors: G
authors: Maire
authors: Shabin
authors: S
authors: Nanji
authors: Martin C
authors: MC
authors: Chang
authors: Matthew
authors: M
authors: Vlasschaert
authors: Jason
authors: J
authors: Dodge
authors: Terence J
authors: TJ
authors: Colgan
mesh_terms: D050761:Cyclin-Dependent Kinase Inhibitor p57 / Q000032:analysis; D003937:Diagnosis, Differential; D003954:Diagnostic Services; D005260:Female; D005838:Genotype; D006801:Humans; D006828:Hydatidiform Mole / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D007150:Immunohistochemistry; D010922:Placenta Diseases / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D011247:Pregnancy; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology
chemical_list: C493964:CDKN1C protein, human; D050761:Cyclin-Dependent Kinase Inhibitor p57